Gary C. Doolittle

3.0k total citations
75 papers, 1.3k citations indexed

About

Gary C. Doolittle is a scholar working on Public Health, Environmental and Occupational Health, Oncology and General Health Professions. According to data from OpenAlex, Gary C. Doolittle has authored 75 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Public Health, Environmental and Occupational Health, 24 papers in Oncology and 17 papers in General Health Professions. Recurrent topics in Gary C. Doolittle's work include Telemedicine and Telehealth Implementation (21 papers), Economic and Financial Impacts of Cancer (13 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Gary C. Doolittle is often cited by papers focused on Telemedicine and Telehealth Implementation (21 papers), Economic and Financial Impacts of Cancer (13 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Gary C. Doolittle collaborates with scholars based in United States, United Kingdom and Russia. Gary C. Doolittle's co-authors include Pamela Whitten, A Allen, David J. Cook, Michael Mackert, Frances S Mair, Ryan Spaulding, Arthur R. Williams, Carl May, David Bodensteiner and F Otto and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Gary C. Doolittle

70 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary C. Doolittle United States 21 658 456 327 177 119 75 1.3k
Karen Luxford Australia 19 429 0.7× 800 1.8× 407 1.2× 96 0.5× 112 0.9× 51 1.6k
Sabe Sabesan Australia 25 833 1.3× 542 1.2× 762 2.3× 137 0.8× 222 1.9× 92 1.9k
Sara Urowitz Canada 19 455 0.7× 807 1.8× 321 1.0× 123 0.7× 66 0.6× 44 1.6k
Jeffrey Belkora United States 25 622 0.9× 1.1k 2.4× 587 1.8× 69 0.4× 213 1.8× 79 1.9k
Fiona Ross United Kingdom 22 275 0.4× 699 1.5× 376 1.1× 55 0.3× 47 0.4× 75 1.7k
Alison Rein United States 11 613 0.9× 545 1.2× 247 0.8× 42 0.2× 103 0.9× 17 1.4k
Susan Catt United Kingdom 15 631 1.0× 491 1.1× 606 1.9× 25 0.1× 136 1.1× 29 1.6k
Katharine A. Rendle United States 21 306 0.5× 537 1.2× 507 1.6× 52 0.3× 124 1.0× 90 1.5k
Sanghee Kim South Korea 21 442 0.7× 308 0.7× 316 1.0× 18 0.1× 53 0.4× 165 1.5k
Benjamin W. Lamb United Kingdom 28 683 1.0× 829 1.8× 773 2.4× 47 0.3× 320 2.7× 121 2.7k

Countries citing papers authored by Gary C. Doolittle

Since Specialization
Citations

This map shows the geographic impact of Gary C. Doolittle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary C. Doolittle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary C. Doolittle more than expected).

Fields of papers citing papers by Gary C. Doolittle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary C. Doolittle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary C. Doolittle. The network helps show where Gary C. Doolittle may publish in the future.

Co-authorship network of co-authors of Gary C. Doolittle

This figure shows the co-authorship network connecting the top 25 collaborators of Gary C. Doolittle. A scholar is included among the top collaborators of Gary C. Doolittle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary C. Doolittle. Gary C. Doolittle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Doolittle, Gary C., et al.. (2024). Screening log: Challenges in community patient recruitment for gynecologic oncology clinical trials. Contemporary Clinical Trials Communications. 42. 101379–101379.
2.
Mushtaq, Muhammad Umair, Haitham Abdelhakim, Luke V. Selby, et al.. (2024). Reduced dose fludarabine/cyclophosphamide lymphodepletion for tumor-infiltrating lymphocytes therapy (LN-144, lifileucel) in metastatic melanoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9608–TPS9608. 2 indexed citations
3.
Eroglu, Zeynep, Janice M. Mehnert, Anita Giobbie‐Hurder, et al.. (2023). Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).. Journal of Clinical Oncology. 41(16_suppl). 9511–9511. 3 indexed citations
4.
Mudaranthakam, Dinesh Pal, Byron J. Gajewski, Hope Krebill, et al.. (2022). Barriers to Clinical Trial Participation: Comparative Study Between Rural and Urban Participants. JMIR Cancer. 8(2). e33240–e33240. 18 indexed citations
5.
Gurley‐Calvez, Tami, et al.. (2021). Economics of Using Telemedicine to Supplement Hospice Care in Rural Areas. Journal of Palliative Medicine. 24(10). 1461–1466. 14 indexed citations
6.
Milton, Denái R., William H. Sharfman, Bret Taback, et al.. (2021). An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. OncoImmunology. 10(1). 1984059–1984059. 5 indexed citations
7.
Haymaker, Cara, Robert H.I. Andtbacka, Douglas B. Johnson, et al.. (2020). 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma. Annals of Oncology. 31. S736–S736. 15 indexed citations
8.
Fulbright, Joy M., Gary C. Doolittle, Jennifer R. Klemp, et al.. (2015). A Collaborative Step-Wise Process to Implementing an Innovative Clinic for Adult Survivors of Childhood Cancer. Journal of Pediatric Nursing. 30(5). e147–e155. 12 indexed citations
9.
Doolittle, Gary C., et al.. (2011). The Decreasing Cost of Telemedicine and Telehealth. Telemedicine Journal and e-Health. 17(9). 671–675. 36 indexed citations
10.
Whitehead, Robert P., Sheryl McCoy, Saul E. Rivkin, et al.. (2006). A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study. Investigational New Drugs. 24(6). 515–520. 55 indexed citations
11.
Doolittle, Gary C., et al.. (2005). Online Cancer Services: Types of Services Offered and Associated Health Outcomes. Journal of Medical Internet Research. 7(3). e35–e35. 14 indexed citations
12.
Whitten, Pamela, et al.. (2003). Telehospice carries end-of-life care over the lines. Nursing Management. 34(11). 36–39. 19 indexed citations
13.
Allen, Ace, et al.. (1999). An analysis of the suitability of home health visits for telemedicine. Journal of Telemedicine and Telecare. 5(2). 90–96. 32 indexed citations
14.
Wootton, Richard, Maria Loane, Frances S Mair, et al.. (1998). The potential for telemedicine in home nursing. Journal of Telemedicine and Telecare. 4(4). 214–218. 27 indexed citations
15.
Doolittle, Gary C., et al.. (1997). Autoimmune Thrombocytopenic Purpura Associated With Hyperthyroidism in a Single Individual. Southern Medical Journal. 90(9). 933–936. 9 indexed citations
16.
Doolittle, Gary C., et al.. (1996). First report of a B cell lymphoproliferative disorder arising in a patient treated with immune suppressants for severe aplastic anemia. American Journal of Hematology. 52(2). 108–113. 13 indexed citations
17.
Doolittle, Gary C., et al.. (1996). Paraneoplastic pemphigus in a patient with non-Hodgkin's lymphoma. American Journal of Hematology. 52(1). 58–59. 11 indexed citations
18.
Bodensteiner, David & Gary C. Doolittle. (1993). Adverse Haematological Complications of Anticancer Drugs. Drug Safety. 8(3). 213–224. 16 indexed citations
19.
Doolittle, Gary C., David Bodensteiner, Barry Skikne, & Mammo Amare. (1991). Therapy of aplastic anemia with sequential antithymocyte globulin and cyclosporin. American Journal of Hematology. 36(2). 144–146. 4 indexed citations
20.
Doolittle, Gary C., et al.. (1988). Malignancy-Induced Lactic Acidosis. Southern Medical Journal. 81(4). 533–536. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Luxford Breakdown of academic impact, for papers by Sabe Sabesan Breakdown of academic impact, for papers by Sara Urowitz Breakdown of academic impact, for papers by Jeffrey Belkora Breakdown of academic impact, for papers by Fiona Ross Breakdown of academic impact, for papers by Alison Rein Breakdown of academic impact, for papers by Susan Catt Breakdown of academic impact, for papers by Katharine A. Rendle Breakdown of academic impact, for papers by Sanghee Kim Breakdown of academic impact, for papers by Benjamin W. Lamb
Rankless by CCL
2026